



A Case of Mucinous Cystadenoma Carcinoma

**Vaibhav G. Hatwar^{1*}, Ranjana Sharma², Mayur Wanjari³, Pratibha Wankhede³,
Sagar Alwadkar³ and Hina Rodge⁴**

¹ Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.

² Department of Medical Surgical Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.

³ Department of Community Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.

⁴ Department of Child Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i52A33568

Editor(s):

(1) Dr. Syed A. A. Rizvi, Nova Southeastern University, USA.

Reviewers:

(1) Riccardo Beltrami, The University of Pavia, Italy.

(2) Lucia Maria Jaeger de Carvalho, Universidade Federal do Rio de Janeiro, Brazil.

Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here:

<https://www.sdiarticle5.com/review-history/75948>

Case Study

Received 22 August 2021
Accepted 28 October 2021
Published 27 November 2021

ABSTRACT

Introduction: Mucinous Cystadenoma carcinoma is a type of tumor in the cyst adenocarcinoma grouping it can occur in the breast as well as the ovary. Tumors are normally multicystic with various smooth thin-walled cysts. Within the cyst is found an emergence or cellular debris.

Patient History: The female patient 63-year-old who was admitted to AVBRH on the date 21/05/2021 in the obstetric and gynae ward with a chief complaint of generalized weakness, loss of appetite, fever for 2 days 7 days ago, 2-3 fever spikes and burning micturition. All over investigation observed like blood and urine investigation, CT scan of the abdomen, histopathology then the final diagnosis is confirmed as mucinous Cystadenoma carcinoma.

Pharmacology: The patient was treated with antibacterial medicine, antibiotics, and diabetics, thyroxin stimulating drugs, etc. Management: Inj. Ceftriaxone 1gm 12 hourly, Inj.-pizat 4.45 gm, 8 hourly, tab. Gimipride 0.5 mg with tab. Metformin 500 mg 12 hourly, tab. Thyrox 62.5 mcg, tab

telmisartan 40 mg with tab. Chlorthalidone 12.5/12.5 mg 12 hourly, Inj.-pan 40 mg, 12 hourly, Inj.-Neomol 100 ml, and Tablet- nitrofurantoin 6 hourly.

Nursing Management: Monitor the vital sign, monitor nutritional status and monitor random blood sugar. Maintained bed rest of patient, managed the pain level of the patient. The patient was assessed for risk of bleeding.

Conclusion: The patient was admitted to the hospital with the chief complaint of generalized weakness, loss of appetite, fever for 2 days 7 days ago, 2-3 fever spikes and burning micturition. and the patient was admitted to AVBR Hospital in the obstetric and gynae ward, immediate treatment was started by a health team member and all possible treatments were given and now the patient's condition is satisfactory.

Keywords: Mucinous cystadenoma carcinoma; dj stenting; medical management; pharmacology.

1. INTRODUCTION

Mucinous Cystadenoma carcinoma is a benign cystic tumor lined by a mucinous epithelium. It is a type of cystic adenoma (cystadenoma) [1,2]. Mucinous cystadenomata may arise in several locations however mucinous cystadenoma at different locations is not generally considered to be related to one another [3,4].

1.1 Incidence

Benign mucinous cystadenoma composed 80% of the mucinous ovarian tumor and 20 to 25% of benign ovarian tumors overall. The peak incidence occurs between 30 and 50 years of age [5]. Benign tumors are bilateral in 5 to 10% of the cases.

1.2 Objective

1. To know general idea regarding disease condition.
2. To explore knowledge regarding pharmacology, medical and nursing management.

2. PATIENT INFORMATION

2.1 Patient Present History

The female patient 63-year-old who was admitted to AVBRH on the date 21/05/2021 in the obstetric and gynae ward with a chief complaint of generalized weakness, loss of appetite, fever for 2 days 7 days ago, 2-3 fever

spikes and burning micturition. All over investigation observed like blood and urine investigation, CT scan of the abdomen, histopathology then the final diagnosis is confirmed as mucinous Cystadenoma carcinoma [6].

2.2 Past History

The patient was not having any history of communicable disease, asthma, tuberculosis, but the patient was having diabetes. The patient was COVID - positive. The patient had undergone a DJ stenting surgical procedure on the right side on date 25/05/2021

2.3 Causes

Unknown, Genetic inheritance

2.4 Clinical Finding

1. Emesis
2. Fatigue
3. Indigestion
4. Constipation
5. Urinary incontinence
6. Abdominal or pelvic pain
7. Increasing Abdominal girth

2.5 Diagnosis Evaluation

1. History collection-Done.
2. Physical examination- Done
3. CT scan -Done
4. Others: ECG, CBC, Histopathology

2.6 Blood Investigation Report

Investigation	Patient Value	Normal Value	Justification
Complete Blood Count			
1. HB%	11%	13-15.5%	Decreased
	92.4cub.micron	80-90cub.micron	Increased

Investigation	Patient Value	Normal Value	Justification
2. MCV	31.2 Pico gm.	26.5-33.5 Pico gm.	Normal
3. MCH	3.51million/cu.mm	4.5-6 million/cu.mm	Decreased
4. Total RBC Count	9600 cu.mm	4000-11000 cu.mm	Normal
5. Total WBC Count	2.4 lacs/cu.mm	1.5-4 lacs/cu.mm	Normal
6. Total platelet count	04 %	4-10%	Normal
7. Monocytes			
KFT			
1. Urea	15 mg%	18-40 mg%	Increased
2. Creatinine	0.9 mg%	0.7- 1.5 mg%	Normal
3. Sodium	133 meq/l	136-145 meq/l	Decreased
4. Potassium	4.4 mmeq/l	3.5 – 5.1mmeq/l	Normal
LFT			
1. Total protein	7.2 gm. %	6-8 gm. %	Normal
2. Albumin	3.7 gm. %	3-5 gm. %	Normal
3. Total bilirubin	0.8 mg%	0.3 – 1 mg%	Normal

RTPCR: - POSITIVE

2.6 CT SCAN

Previous pelvic mass lesion presently measures approximately 5.5 x 6*5.2 shown to decrease in size as compared to previous with mild extension into the urinary bladder lumen. Lesion posteriorly involving adjacent rectosigmoid wall thickening a significant change in the size of compared to the previous CECT

3. MEDICAL THERAPY

3.1 Pharmacology Therapy

1. Antibacterial medicine
2. Antibiotics
3. Antidiabetics
4. Thyroxin stimulating drug

3.2 Medical Management

Now patient treatment in the ward is Inj. Ceftriaxone 1gm 12hourly, Inj.-piptaz 4.45 gm., 8 hourly, tab. Glimepiride 0.5mg with tab. Metformin 500mg 12 hourly, tab. Thyroxin 62.5 mcg, tab telmisartan 40mg with tab. Chlorthalidone 12.512.5 mg 12 hourly, Inj.-pan 40mg, 12 hourly, Inj.- Neomol 100ml, and Tablet-nitrofurantoin 6 hourly.

3.3 Nursing Management

The nurse is in charge of prescribing the medication and assessing its positive and detrimental effects on the patients [7,8]. The

pharmacologic therapy type and dosage are determined by the combination of these effects. Actions to assess clinical effectiveness in nursing include:

Observe for signs of difficulty with gait or coordination and monitored for changes in blood sugar levels with co-administered drugs, monitored for pain level and bleeding.

Perform an active, passive and isotonic range of motion exercise as appropriate.

Check the bowel and bladder pattern of the patient.

3.4 Nursing Diagnosis

1. Impaired thermoregulation related to hyperthermia
2. Activity intolerance related to generalized weakness
3. Burning micturition related to infection secondary disease condition
4. The imbalanced nutritional pattern is less than body requirement related to low caloric intake and poor outcomes associated with anorexia.
5. Deficient knowledge about self-care activities related to reportable signs and symptoms, treatment modalities and medications.

3.5 Collaborative Problems / Potential Complications

1. Torsion
2. Intracyst huge
3. Infection
4. Rupture
5. Malignancy
6. Pseudomyxoma peritonei

3.6 Follow up

A referral to home care may be suggested for a hospitalized patient depending upon the physical condition of the patient and the availability of family assistance. The patients with mucinous Cystadenoma carcinoma had impaired physical stamina often need home transfer assistance after hospitalization. The home care nurse's assessment of the home's physical environment is important. Suggestions to adapt the home environment to meet the limitation of the patient's activity are significant.

4. DISCUSSION

Mucinous Cystadenoma carcinoma is a type of tumor in the cystadenocarcinoma grouping it can occur in the breast as well as the ovary [9]. Tumors are normally multiocular with various smooth thin-walled cysts. Within the cyst is found an emergence or cellular debris [10].

4.1 Strength

The patient was 63 years female tolerate all the medication and well response around 1 month to the treatment of the hospital which was given as a treatment.

5. CONCLUSION

Mucinous carcinoma is an invasive type of cancer that begins in an internal organ that produces much mucin, the primary ingredient of mucus. The abnormal cells inside this type of tumor are floating in the mucin, and the mucin becomes a part of the tumor. Mucinous Cystadenoma carcinoma is a benign cystic tumor lined by a mucinous epithelium. It is a type of cystic adenoma (cystadenoma).

INFORMED CONSENT

Before taking this case, information was given to the patients and relatives and informed consent

was obtained from the patient as well as relatives.

ETHICAL APPROVAL

We conducted our research after obtaining proper IEC approval.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Uterine cervical elongation and prolapse during pregnancy: an old unsolved problem.
2. Stumbar SE, Stevens M, Feld Z, Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management. Primary Care; 2019.
3. Castle PE, Pierz A, (At Least) Once in Her Lifetime: Global Cervical Cancer Prevention. Obstetrics and gynecology clinics of North America; 2019. [PubMed PMID: 30683258]
4. Krishnan S, Madsen E, Porterfield D, Varghese B. Advancing cervical cancer prevention in India: Implementation science priorities. Oncologist. 2013; 18:1285–97. [PMC free article] [PubMed] [Google Scholar]
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–917.
6. Jacob M. Information, education & communication: Corner stone for preventing cancer of the cervix. Indian J Med Res. 2012;136:182–4. [PMC free article]
7. Annamma Jacob. A Comprehensive textbook of Midwifery & Gynecological nursing, 4th edition, Published by Jaypee brethren's medical publishers, New Delhi. 2015;857-866.
8. Dutta DC. Textbook of gynaecology. 5th edition. Kolkata: New Central Book; 2008.
9. Yogev Y, Horowitz ER, Ben-Haroush A, Kaplan B. Clin Exp Obstet Gynecol; 2003.

- [PMID: 14664405]
10. Alevén V, Stahl E, Schworm S, Fischer F, Wallace R. Help seeking and help design in interactive learning environments. *Review of Educational Research*. 2003;73: 277-320.

© 2021 Hatwar et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/75948>